Inmagene Receives FDA’s IND Clearance for OX40 Antagonist

SAN DIEGO and SHANGHAI and SYDNEY, April 30, 2022 /PRNewswire/ — Inmagene Biopharmaceuticals (“Inmagene”) announces that the U.S. Food and Drug Administration (FDA) has cleared drug candidate IMG-007, a monoclonal antibody against OX40, to proceed to Phase I clinical development….

Click here to view original post